Sign In
|
Register
|
About Los Altos
|
Contact Us
Los Altos, CA
September 01, 2020 1:26pm
7-Day Forecast
|
Traffic
Los Altos News
Local News
Bay Area News
Business
Technology
Real Estate
Sports
High School Sports
Los Altos Gas Prices
Ski And Snow Reports
Financial Markets
Bagels
Bakery
Barbecue
Coffee Houses
Continental
Deli
Fast Food
French
Ice Cream / Frozen Yogurt
Italian
Mexican
Pizza
Steaks, Chops
Sushi
Vietnamese
Wine
Museums
Family Fun
Arts & Culture
Parks
Annual Events
Accommodations
Hotel and Motel Management
Hotels & Resorts
Apartments
Art & Culture
Galleries & Dealers
Museums
Associations, Foundations and Organizations
Business & Professional Clubs
Civic, Social and Fraternal
Non-Profits
Professional & Trade Associations
Attractions & Entertainment
Amusement & Water Parks
Bowling, Billiards & Video Games
General Attractions
Golfing
Horseback Riding
Movie Theatres
Theatre
Automotive
Auto Rental
Dealers - New
Dealers - Used
Mobile Home Dealers
Motorcycles
Parts & Supplies
Radio & Alarm Systems
Repair & Service
Tires
Towing
Beauty & Fitness
Barbers
Beauty Salons
Cosmetics
Dance Clubs & Studios
Health Clubs & Gyms
Manicures
Nutrition
Skin Treatment
Yoga
Business & Professional Services
Appraisers
Building Maintenance & Janitorial
Business & Labor Organizations
Computer & Audio Visual Services
Consultants
Courier, Delivery & Messenger Service
Credit Check & Collection Agencies
Data Processing Service
Employment Services, Placement & Agencies
Engineer and Architect Services
Equipment & Supplies, Commercial & Industrial
Graphic Design & Art
Human Resource Services
Internet Services
Marketing & Advertising Services
Media Services
Notary Services
Photography
Printing & Publishing
Public Relations & Publicity
Security & Investigative Services
Shipping, Packaging & Postal Services
Signs & Banners
Staffing & Support Services
Translators & Interpreters
Contractors
Architects
Building Contractors & Consultants
Drywall, Plastering & Insulation
Electric
General Contractors
Heating, Cooling & AC
Landscaping
Painting & Wallcovering
Plumbing
Special Trade Contractors
Domestic Services
Child Care Services
Housecleaning
Pet Sitting and Day Care
Education
Colleges & Universities
Cont. Education
Elementary Schools
High Schools
Libraries
Preschools & Childcare
Private & Parochial
Public
Tutoring
Employment
Employment Agencies
Find or Post a Job
Temporary Help & Employment Contractors
Financial Services
Accountants & Tax
Banks & Credit Unions
Bookkeeping
Financial Brokers and Dealers
Financial Consultants
Financial Planning and Services
Investments
Loans
Mortgage Lenders
Golf
Government
Post Offices
State Government
Hair Salons
Health and Medicine
Alternative Medicine / Acupuncture
Chiropractors
Counseling
Dentistry
Dermatologists
Drug Stores & Pharmacies
Eye Care
Health Care Professionals
Home Health Care
Hospitals & Clinics
Medical Doctors
Medical Equipment & Supplies
Nutrition
Physical Therapist
Physicians & Surgeons
Social Services
Specialists - Health Care Professionals
Home & Garden
Appliances
Bed & Bath
Building Materials & Hardware
Cleaning Supplies & Services
Contractors
Domestic Services
Doors, Windows & Drapery
Floor Coverings
Furniture
Handyman
Home Improvement Centers
Interior Design & Decorating
Kitchen
Lamps & Lighting
Lawn & Garden
Locksmiths
Lumber
Nurseries & Garden Centers
Painting & Wallcoverings
Pest Control
Plumbing
Pools, Spas & Saunas
Safety & Security
Sewage & Septic Systems
Sprinklers
Insurance
Agents & Brokers
Health
Laser Hair Removal
Legal
Attorneys
Legal Services
Manufacturing & Industrial
Agriculture
Audio & Visual
Building Materials
Computers, Electronics & Telecommunications
Electronic Equipment
Food & Beverage
Industrial Supplies & Services
Machine Shops
Textiles & Apparel
Media
Radio Stations
Television Stations
Meeting & Event Planning
Event Facilities
Exhibit Designers
Meeting Planners
Party Rentals & Entertainment
Miscellaneous
Nightlife
Live Music
Personal Service
Child Care
Dry Cleaning and Laundry
Shoe Repair
Tailors and Alterations
Pets
Pet Grooming
Pet Supplies & Food - Retail
Veterinary Hospitals
Plastic Surgery
Aesthetic Surgeon
Plastic Surgeon
Real Estate
Appraisers
Assisted Living & Elder Care Service
Commercial
Developers
Property Management
Real Estate Agents and Brokers
Residential
Schools
Title Companies
Religion
Relocation
Storage
Restaurants
Bagels
Bakery
Barbecue
Coffee Houses
Continental
Deli
Fast Food
French
Ice Cream / Frozen Yogurt
Italian
Mexican
Pizza
Steaks, Chops
Sushi
Vietnamese
Wine
Shopping
Accessories
Antiques
Books
Cellular & Wireless
Children's and Infants Clothing
Clothing
Computer and Computer Software
Department Stores
Electronics
Flowers
Furniture
Gas Stations
Gifts & Specialty Shops
Grocery Stores
Health Food Stores
Home Improvement
Jewelry
Men's Clothing Stores
Pharmacies
Resale Shops
Shoe Stores
Shopping Centers & Malls
Smoke Shops
Sporting Goods
Thrift Stores
Toy Stores
Videos
Women's Clothing Stores
Spas
Day Spas
Resort Spas
Sports & Recreation
Arenas and Venues
Associations & Clubs
Equestrian
Golf Equipment & Supplies
Instruction
Martial Arts
Recreation Facilities
Skateboarding
Technology
Communications
Computer Services & Consultants
Internet Advertising & Services
Semiconductor
Software
Travel & Transportation
Airlines & Airports
Auto Rentals
Bus Lines & Charters
Taxi, Limousine & Shuttle
Tours & Excursions
Travel Agencies
Weddings
Cakes & Caterers
Your Business Here
Classifieds
Cars
Forums
Coupons
News Archives
Contests
Jobs
Search Hotels in Los Altos
CHECK-IN:
CHECK-OUT:
ROOMS:
1
2
3
4
Find A Business
or
Browse Listings
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Bristol Myers Squibb
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Augtyro™ (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors
February 14, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb and RayzeBio Announce Expiration of HSR Act Waiting Period
February 12, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
RYZB
Bristol Myers Squibb Announces Acceptance of U.S. and EU Regulatory Filings for Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Opdivo in Resectable Non-Small Cell Lung Cancer
February 07, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Named One of America’s Most JUST Companies by JUST Capital and CNBC
February 05, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb and 2seventy bio Share Update on U.S. FDA Oncologic Drugs Advisory Committee Meeting for Abecma in Triple-Class Exposed Multiple Myeloma Based on KarMMa-3 Study
February 05, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
TSVT
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023
February 02, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Regulatory Applications Accepted in the U.S. and Japan for Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel) in Relapsed or Refractory Follicular Lymphoma (FL) and Relapsed or Refractory Mantle Cell Lymphoma (MCL)
January 30, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Subcutaneous Nivolumab (nivolumab and hyaluronidase) Shows Noninferiority Compared to Intravenous Opdivo (nivolumab) in Advanced or Metastatic Clear Cell Renal Cell Carcinoma in CheckMate -67T Trial
January 27, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma
January 26, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Completes Acquisition of Mirati Therapeutics, Strengthening and Diversifying Oncology Portfolio
January 23, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Eight-Year Data for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Continue to Demonstrate Longest Survival Benefit vs. Sunitinib Reported in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
January 22, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Long-Term Survival Benefits After Four Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma
January 22, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
EXEL
Opdivo (nivolumab) Plus Yervoy (ipilimumab) Reduced the Risk of Disease Progression or Death by 79% Versus Chemotherapy in Patients with Microsatellite Instability-High or Mismatch Repair Deficient Metastatic Colorectal Cancer in CheckMate -8HW Trial
January 20, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Data at ASCO GU 2024 Showcase Transformative Research in the Treatment of Genitourinary Cancers
January 17, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
European Medicines Agency Validates Bristol Myers Squibb’s Application for Repotrectinib for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer and NTRK-Positive Solid Tumors
January 02, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio
December 26, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
RYZB
Bristol Myers Squibb to Present at J.P. Morgan’s 42nd Annual Healthcare Conference
December 22, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb to Participate in the 2024 Goldman Sachs Healthcare C-Suite Unscripted Conference
December 20, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Provides Update on RELATIVITY-123 Trial Evaluating the Fixed-Dose Combination of Nivolumab and Relatlimab in Patients with Previously Treated Metastatic Microsatellite Stable (MSS) Colorectal Cancer
December 15, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb to Report Results for Fourth Quarter 2023 on February 2, 2024
December 15, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Two Early Studies Evaluating Potential First-in-Class CELMoD™ Agent Golcadomide for the Treatment of Non-Hodgkin Lymphomas Presented at ASH 2023
December 11, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Announces Data at ASH 2023 from Diverse Multiple Myeloma Pipeline, Underscoring Range of Tailored Treatment Approaches to Address Unique Patient Needs
December 11, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Abecma Delivers Sustained Progression-Free Survival Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Longer-Term Follow-up from KarMMa-3
December 11, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
TSVT
SystImmune and Bristol Myers Squibb Announce a Global Strategic Collaboration Agreement for the Development and Commercialization of BL-B01D1
December 11, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Presents New Data at ASH 2023 Demonstrating Clinical Benefit Across B-cell Malignancies with Breyanzi as a Second-Line Treatment in High-Risk Follicular Lymphoma and in Relapsed or Refractory Chronic Lymphocytic Leukemia
December 10, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Presents Primary Efficacy and Safety Analysis of the Phase 3 COMMANDS Trial of Reblozyl for Treatment of Anemia in Erythropoiesis Stimulating Agent-Naïve Patients with Lower-Risk Myelodysplastic Syndromes at ASH 2023
December 09, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Announces Phase 3 CheckMate -8HW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Compared to Chemotherapy in Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer Meets Primary...
December 07, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Announces Additional $3 Billion Share Repurchase Authorization
December 07, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Announces Dividend Increase
December 06, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy for the First-Line Treatment of Adult Patients with Unresectable or Metastatic...
December 05, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
About Us
|
Contact Us
|
Privacy Policy
|
User Agreement
|
Advertise With Us
|
Site Map
Home
|
News
|
Travel
|
Restaurants
|
Nightlife
|
Things To Do
|
Shopping
|
Events
|
Directory
|
Real Estate
|
Blog
|
More
Copyright © 2010-2020 LosAltos.com & California Media Partners, LLC. All rights reserved.